Screen Failure Rates in Contemporary Randomized Clinical Phase II/III Therapeutic Trials in Genitourinary Malignancies

This publication has 61 references indexed in Scilit:

• Pazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma
  New England Journal of Medicine, 2013
• Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
  New England Journal of Medicine, 2012
• Randomized Phase II/III Trial Assessing Gemcitabine/Carboplatin and Methotrexate/Carboplatin/Vinblastine in Patients With Advanced Urothelial Cancer Who Are Unfit for Cisplatin-Based Chemotherapy: EORTC Study 30986
  Journal of Clinical Oncology, 2012
• Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial
  The Lancet, 2011
• Abiraterone and Increased Survival in Metastatic Prostate Cancer
  New England Journal of Medicine, 2011
• Adjuvant Androgen Deprivation for High-Risk Prostate Cancer After Radical Prostatectomy: SWOG S9921 Study
  Journal of Clinical Oncology, 2011
• Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
  New England Journal of Medicine, 2010
• Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial
  The Lancet, 2008
• Sorafenib in Advanced Clear-Cell Renal-Cell Carcinoma
  New England Journal of Medicine, 2007
• The price of innovation: new estimates of drug development costs
  Journal of Health Economics, 2003